Chembio Diagnostics signed an initial R&D collaboration with Pall related to its Dual Path Platform (DPP™). The transaction is a two-phase funded feasibility study that will help ascertain performance characteristics of DPP when used in conjunction with certain markers that are of interest to Pall.
If performance meets or exceeds certain levels, Chembio anticipates that the parties would proceed to negotiation of license, development, and manufacturing agreements related to these and potentially other markers.
Chembio reports that the DPP immunoassay demonstrates improved detectability, sensitivity, and specificity compared to single path lateral flow (SPLF) tests. It is a lateral flow technology that employs separate membrane strips for sample migration and test reagents. It allows for complete control and management of the sample flow, hence the immunological reaction is much more efficient than conventional SPLF tests, according to Chembio.